GILD
NEUTRAL
$132.9
Live
Gilead Sciences, Inc. · NASDAQ
Target $158.36
(+19.2%)
$93.37
52W Range
$157.29
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 23, 2026
Market cap
$164.96B
P/E
19.6
ROE
40.7%
Profit margin
28.9%
Debt/Equity
1.13
Dividend yield
2.47%
AI Analysis
AI-powered fundamental assessment
Confidence
85%
GILD presents a stable financial profile with a Piotroski F-Score of 4/9 and a valuation that sits between a conservative Graham Number ($52.83) and a growth-based Intrinsic Value ($200.01). The company exhibits exceptional profitability with an ROE of 40.66% and a very attractive PEG ratio of 0.38, suggesting significant undervaluation relative to earnings growth. However, bearish technicals (0/100) and consistent insider selling by the CEO and CFO create significant short-term headwinds. While fundamentals are robust, the lack of price momentum and insider sentiment temper a bullish outlook.
Key Strengths
Exceptional profitability with 78.84% gross margins and 40.66% ROE
Highly attractive PEG ratio of 0.38 indicating undervaluation relative to growth
Strong earnings growth (YoY 23.40%) and consistent history of beating estimates
Sustainable dividend profile with a 46.61% payout ratio
Strong analyst consensus with a target price of $158.36
Key Risks
Bearish insider sentiment with selling from the CEO and CFO
Weak technical trend (0/100) indicating strong downward or stagnant momentum
Modest revenue growth (4.70%) compared to high earnings growth
High Price-to-Book ratio (7.27) suggesting a premium over book value
Debt-to-Equity ratio of 1.13 indicates moderate leverage
AI Fair Value Estimate
Based on comprehensive analysis
$155.6
+17.1% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
69
Strong
75
70
80
50
70
AI Verdict
Fundamental Strength vs. Sentiment Weakness
Key drivers: High ROE, Low PEG, Insider Selling, Bearish Technicals
Confidence
90%
Value
75/100
Ref P/E, PEG, Graham Number
Positives
- Low PEG (0.38)
- Forward P/E (13.81) is lower than current P/E
Watchpoints
- Current price is significantly above Graham Number ($52.83)
Future
70/100
Ref Growth rates
Positives
- Strong earnings growth (23.4%)
- Positive analyst target price
Watchpoints
- Slow revenue growth (4.7%)
Past
80/100
Ref Historical trends
Positives
- Strong 5Y change (+144.5%)
- Consistent earnings beat track record
Watchpoints
- Recent Q/Q EPS decline (-28.4%)
Health
50/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio (1.55) shows adequate liquidity
Watchpoints
- Piotroski F-Score of 4/9 is only 'Stable', not 'Strong'
Dividend
70/100
Ref Yield, Payout
Positives
- Healthy payout ratio (46.61%)
- Consistent dividend rate
Watchpoints
- Yield (2.47%) is modest
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$132.9
Analyst Target
$158.36
Upside/Downside
+19.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for GILD and closest competitors.
Updated 2026-04-22
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
GILD
Gilead Sciences, Inc.
Primary
|
+144.5% | +69.7% | +29.3% | +10.8% | -3.2% | -4.9% |
|
ISRG
Intuitive Surgical, Inc.
Peer
|
+56.7% | +55.1% | -0.6% | +1.6% | -2.6% | +1.4% |
|
PFE
Pfizer Inc.
Peer
|
+1.1% | -17.2% | +24.9% | +8.7% | +4.8% | +4.8% |
|
ABT
Abbott Laboratories
Peer
|
-10.8% | +2.5% | -18.4% | -21.1% | -7.6% | -1.9% |
|
AMGN
Amgen Inc.
Peer
|
+65.2% | +59.9% | +16.5% | +26.4% | -8.8% | +1.0% |
GIL
Gilead Sciences, Inc.
Primary
5Y
+144.5%
3Y
+69.7%
1Y
+29.3%
6M
+10.8%
1M
-3.2%
1W
-4.9%
ISR
Intuitive Surgical, Inc.
Peer
5Y
+56.7%
3Y
+55.1%
1Y
-0.6%
6M
+1.6%
1M
-2.6%
1W
+1.4%
PFE
Pfizer Inc.
Peer
5Y
+1.1%
3Y
-17.2%
1Y
+24.9%
6M
+8.7%
1M
+4.8%
1W
+4.8%
ABT
Abbott Laboratories
Peer
5Y
-10.8%
3Y
+2.5%
1Y
-18.4%
6M
-21.1%
1M
-7.6%
1W
-1.9%
AMG
Amgen Inc.
Peer
5Y
+65.2%
3Y
+59.9%
1Y
+16.5%
6M
+26.4%
1M
-8.8%
1W
+1.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
19.6
Forward P/E
13.81
PEG Ratio
0.38
P/B Ratio
7.27
P/S Ratio
5.6
EV/Revenue
6.14
EV/EBITDA
12.4
Market Cap
$164.96B
Profitability
Profit margins and return metrics
Profit Margin
28.9%
Operating Margin
37.38%
Gross Margin
78.84%
ROE
40.66%
ROA
12.52%
Growth
Revenue and earnings growth rates
Revenue Growth
+4.7%
Earnings Growth
+23.4%
Q/Q Revenue Growth
+4.69%
Q/Q Earnings Growth
+22.4%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.13
Moderate
Current Ratio
1.55
Good
Quick Ratio
1.23
Good
Cash/Share
$7.74
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$7.9B
Gross Margin
79.5%
Op. Margin
37.7%
Net Margin
27.5%
Total Assets
$59.0B
Liabilities
$36.4B
Equity
$22.7B
Debt/Equity
1.60x
Operating CF
$3.3B
CapEx
$-0.2B
Free Cash Flow
$3.1B
FCF Yield
94%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-10
$1.74
+12.7% surprise
2025-10-30
$2.43
+43.5% surprise
2025-08-07
$1.56
+5.1% surprise
Healthcare Sector Comparison
Comparing GILD against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
19.6
This Stock
vs
75.44
Sector Avg
-74.0%
(Discount)
Return on Equity (ROE)
40.66%
This Stock
vs
-88.14%
Sector Avg
-146.1%
(Below Avg)
Profit Margin
28.9%
This Stock
vs
-16.28%
Sector Avg
-277.5%
(Weaker)
Debt to Equity
1.13
This Stock
vs
2.66
Sector Avg
-57.6%
(Less Debt)
Revenue Growth
4.7%
This Stock
vs
124.04%
Sector Avg
-96.2%
(Slower)
Current Ratio
1.55
This Stock
vs
4.47
Sector Avg
-65.3%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
GILD
Gilead Sciences, Inc.
|
NEUTRAL | $164.96B | 19.6 | 40.7% | 28.9% | $132.9 | |
|
ISRG
Intuitive Surgical, Inc.
|
NEUTRAL | $165.37B | 59.16 | 16.7% | 28.4% | $465.6 | Compare |
|
PFE
Pfizer Inc.
|
BEARISH | $162.54B | 21.01 | 8.9% | 12.4% | $28.57 | Compare |
|
ABT
Abbott Laboratories
|
NEUTRAL | $176.48B | 27.3 | 13.0% | 14.7% | $101.56 | Compare |
|
AMGN
Amgen Inc.
|
NEUTRAL | $189.67B | 24.71 | 106.1% | 21.0% | $351.85 | Compare |
GILD
Gilead Sciences, Inc.
NEUTRAL
Mkt Cap
$165.0B
P/E
19.6
ROE
40.7%
Price
$132.9
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-15 | MERCIER JOHANNA | Officer | Sale | 3,000 | $422,880 |
| 2026-04-15 | DICKINSON ANDREW D | Chief Financial Officer | Sale | 3,000 | $422,880 |
| 2026-03-27 | O'DAY DANIEL PATRICK | Chief Executive Officer | Sale | 10,000 | $1,368,162 |
| 2026-03-16 | MERCIER JOHANNA | Officer | Sale | 3,000 | $432,690 |
| 2026-03-16 | DICKINSON ANDREW D | Chief Financial Officer | Sale | 3,000 | $432,690 |
| 2026-03-10 | O'DAY DANIEL PATRICK | Chief Executive Officer | Stock Award | 20,026 | - |
| 2026-03-10 | BERGER DIETMAR P. | Officer | Stock Award | 2,133 | - |
| 2026-03-10 | MERCIER JOHANNA | Officer | Stock Award | 6,617 | - |
| 2026-03-10 | CAIN WETTAN KEELEY M | Officer | Stock Award | 1,246 | - |
| 2026-03-10 | DICKINSON ANDREW D | Chief Financial Officer | Stock Award | 6,469 | - |
| 2026-02-27 | O'DAY DANIEL PATRICK | Chief Executive Officer | Stock Award | 38,396 | - |
| 2026-02-27 | O'DAY DANIEL PATRICK | Chief Executive Officer | Sale | 10,000 | $1,447,859 |
| 2026-02-27 | BERGER DIETMAR P. | Officer | Stock Award | 8,530 | - |
| 2026-02-27 | MERCIER JOHANNA | Officer | Stock Award | 11,090 | - |
| 2026-02-27 | CAIN WETTAN KEELEY M | General Counsel | Stock Award | 470 | - |
MERCIER JOHANNA
Officer
2026-04-15
3,000 shares
·
$422,880
DICKINSON ANDREW D
Chief Financial Officer
2026-04-15
3,000 shares
·
$422,880
O'DAY DANIEL PATRICK
Chief Executive Officer
2026-03-27
10,000 shares
·
$1,368,162
MERCIER JOHANNA
Officer
2026-03-16
3,000 shares
·
$432,690
DICKINSON ANDREW D
Chief Financial Officer
2026-03-16
3,000 shares
·
$432,690
O'DAY DANIEL PATRICK
Chief Executive Officer
2026-03-10
20,026 shares
BERGER DIETMAR P.
Officer
2026-03-10
2,133 shares
MERCIER JOHANNA
Officer
2026-03-10
6,617 shares
CAIN WETTAN KEELEY M
Officer
2026-03-10
1,246 shares
DICKINSON ANDREW D
Chief Financial Officer
2026-03-10
6,469 shares
O'DAY DANIEL PATRICK
Chief Executive Officer
2026-02-27
38,396 shares
O'DAY DANIEL PATRICK
Chief Executive Officer
2026-02-27
10,000 shares
·
$1,447,859
BERGER DIETMAR P.
Officer
2026-02-27
8,530 shares
MERCIER JOHANNA
Officer
2026-02-27
11,090 shares
CAIN WETTAN KEELEY M
General Counsel
2026-02-27
470 shares
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
DEF 14A
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
28 analysts
Citigroup
2026-04-13
Buy
Buy
Morgan Stanley
2026-04-10
Overweight
Overweight
Jefferies
2026-03-10
Buy
Needham
2026-02-23
Buy
Buy
Barclays
2026-02-20
Equal-Weight
RBC Capital
2026-02-11
Sector Perform
Sector Perform
Truist Securities
2026-02-11
Buy
Buy
Wells Fargo
2026-02-11
Overweight
Overweight
Cantor Fitzgerald
2026-02-11
Overweight
Overweight
Scotiabank
2026-02-11
Sector Outperform
Sector Outperform
Past News Coverage
Recent headlines mentioning GILD from our newsroom.
Newest → oldest
No matching news yet.